BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

NCT00910429 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

237

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension

Interventions

DRUG: Riociguat (Adempas, BAY63-2521)

Sponsor

Bayer